REGULATORY PRESCREENING

Standard Service 

  • Names are screened for obvious sound-alike and look-alike similar drug names using specific databases per scope of work that usually include US (drugs@FDA), Europe (Article 57), and Canada (drug product database).

  • Names are screened for potential promotional considerations regarding overly fanciful claims.

 

PLUS Services  

  • POCA Screening during the Creative Phase includes the name candidates will be screened using the FDA’s POCA Tool (Combined Similarity Threshold of 70%).   When used during the creative process, the output from the POCA tool is provided to the creative agency and ultimately used to help re-craft name candidates.

  • Word Construction Analysis considers name similarity “beyond POCA” when reviewing cited name pairs for potential conflicts based on word construction (starting letter, prefix, suffix, number of characters, etc.).

  • Percent Derivation is a tool that compares the letters/letter string of the nonproprietary name with the proposed brand name which may lead to confusion in practice among healthcare professionals.   

  • SRC Stem Check is where each name candidate will be screened for USAN and/or INN stems and the evaluation includes whether the brand name appears to be derived from the nonproprietary name and whether the brand name may be confused with a common name.

Remember SafeMark does not create brand names so we work with agencies that create names or pharmaceutical clients that have a list of names that are ready for our prescreening services!   

 

All PLUS PRESCREENING SERVICES are included in the Power of 3 Methodology.

fda.jpg
ema.jpg
mhra.jpg
health canada.jpg
anvisa.jpg
pmda.jpg
kisspng-computer-icons-linkedin-desktop-

Connect with us on LinkedIn

4150 Washington Road 

McMurray, PA 15317 

© Copyright 2020 SafeMark Regulatory Consulting, LLC

 

All rights reserved